The recent report illustrating the nine genes (BRCA1, BRCA2, PALB2, CHEK2, ATM, CDH1, STK11, PTEN, TP53) in which PVs more than doubles the risk of BC and three genes at the two-fold threshold (RAD51C, RAD51D, BARD1) might allow better selection for appropriate gene testing and a reduction in the need for multigene testing which, in the UK, is in the commercial sector [24]. The gene discussed is TP53; the disease is breast cancer.